メキシコのがん疼痛管理市場予測　2024-2032年

Report Overview

KEY FINDINGS
The Mexico cancer pain management market is predicted to grow with a CAGR of 4.95% during the forecast period 2024-2032.

メキシコのがん疼痛管理市場は、2024年から2032年の予測期間中に4.95%のCAGRで成長すると予測されています。

MARKET INSIGHTS
According to the Global Cancer Observatory, Mexico registered 207,154 new cancer cases in 2022. The country experienced 96,210 cancer-related deaths that year, highlighting the significant impact of the disease on the population. Additionally, the number of prevalent cancer cases over five years reached 577,487. Among these, prostate cancer emerged as one of the most frequently diagnosed types, posing a major health challenge for men in Mexico.
Cancer pain treatment is a crucial aspect of cancer care, significantly affecting patients’ quality of life. Addressing cancer pain requires a multifaceted approach, including pharmacological treatments such as cancer pain medications (opioids and non-opioid medications), along with non-pharmacological interventions like physical therapy, psychological support, and complementary therapies. Public health initiatives and policies aimed at improving cancer pain management in Mexico are essential. These initiatives should focus on raising awareness about the importance of pain management in cancer care, advocating for patients’ rights to receive adequate pain relief, and ensuring that pain management is an integral part of cancer treatment protocols.
Collaboration between government agencies, healthcare institutions, non-governmental organizations, and the pharmaceutical industry is necessary to develop and implement effective strategies for advanced cancer pain management. This includes investing in research and development of new cancer pain relief drugs and therapies, as well as improving access to existing treatments. However, managing cancer pain in Mexico faces significant challenges due to concerns about opioid side effects and addiction. Opioids are essential for relieving moderate to severe cancer-related pain. Still, they come with a high risk of side effects such as nausea, constipation, and respiratory depression, as well as potential addiction issues. Addressing these concerns is crucial to ensure effective pain management while mitigating the risks associated with opioid use in the Mexico cancer pain management market.

REPORT SYNOPSIS

SEGMENTATION ANALYSIS
The report on the Mexico cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:
• Opioids
• Morphine
• Fentanyl
• Other Morphines
• Non-Opioids
• Acetaminophen
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
• Nerve Blockers
Market by Disease Indication:
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Other Disease Indications
Inkwood Research’s report on the Mexico cancer pain management market provides in-depth insights as well as the market’s segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis.

COMPETITIVE ANALYSIS
Key players operating in the Mexico cancer pain management market include Pfizer, Teva Pharmaceutical Industries Limited, Mundipharma International, Eli Lilly Company, Grünenthal Pharma GmbH & Co KG, etc.
Teva Pharmaceutical Industries Limited is a pharmaceutical company that manufactures medicines and biopharmaceutical products. The company offers cytotoxic substances, sterile products, hormones, and high-potency drugs. Additionally, Teva produces medications in various forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It focuses on the respiratory, central nervous system (CNS), pain, and oncology therapeutic areas. Teva operates across North America, Europe, Israel, and internationally. Founded in 1901, the company is headquartered in Tel Aviv, Israel.

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT — MEXICO
2.3. COUNTRY ANALYSIS — MEXICO
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.5.1. IMPACT OF COVID-19 ON THE MEXICO CANCER PAIN MANAGEMENT MARKET
2.6. MAJOR MARKET FINDINGS
2.6.1. SURGE IN PERSONALIZED MEDICINE APPROACHES
2.6.2. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES
2.6.3. LIMITATIONS IN CANCER MEASUREMENTS IMPACT HEALTHCARE AND POLICY
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING PREVALENCE OF CANCER IN MEXICO
3.1.2. SURGE IN GERIATRIC POPULATION
3.1.3. ADVANCEMENTS IN PAIN CONTROL AND PALLIATIVE CARE
3.2. KEY RESTRAINTS
3.2.1. REGULATORY CHALLENGES AND APPROVAL DELAYS
3.2.2. LACK OF ACCESS TO OPIOID MEDICINE IN MEXICO
3.2.3. INADEQUATE HEALTHCARE INFRASTRUCTURE
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
4.1.2. ACTIVE R&D BY PHARMACEUTICAL COMPANIES
4.2. PESTLE ANALYSIS
4.2.1. POLITICAL
4.2.2. ECONOMICAL
4.2.3. SOCIAL
4.2.4. TECHNOLOGICAL
4.2.5. LEGAL
4.2.6. ENVIRONMENTAL
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTIONS
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING — MEXICO
4.5. VALUE CHAIN ANALYSIS
4.5.1. RESEARCH & DEVELOPMENT
4.5.2. REGULATORY APPROVAL
4.5.3. MANUFACTURING
4.5.4. DISTRIBUTION
4.5.5. END-USERS
5. MARKET BY DRUG TYPE
5.1. OPIOIDS
5.2. MORPHINE
5.2.1. FENTANYL
5.2.2. OTHER MORPHINES
5.3. NON-OPIOIDS
5.4. ACETAMINOPHEN
5.5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6. NERVE BLOCKERS
6. MARKET BY DISEASE INDICATION
6.1. LUNG CANCER
6.2. COLORECTAL CANCER
6.3. BREAST CANCER
6.4. PROSTATE CANCER
6.5. BLOOD CANCER
6.6. OTHER DISEASE INDICATIONS
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. PFIZER
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCTS
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. TEVA PHARMACEUTICAL INDUSTRIES
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCTS
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. MUNDIPHARMA INTERNATIONAL
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCTS
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. GRÜNENTHAL PHARMA GMBH & CO KG
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCTS
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. ELI LILLY AND COMPANY
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCTS
7.2.5.3. STRENGTHS & CHALLENGES

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – CANCER PAIN MANAGEMENT
TABLE 2: MEXICO CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: MEXICO CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: MEXICO CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: MEXICO CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: MEXICO CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: MEXICO CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 8: LIST OF MERGERS & ACQUISITIONS
TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

List of Figures

LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING — MEXICO
FIGURE 4: VALUE CHAIN ANALYSIS
FIGURE 5: MEXICO CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2023
FIGURE 6: MEXICO CANCER PAIN MANAGEMENT MARKET, BY OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 7: MEXICO CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, 2024-2032 (IN $ MILLION)
FIGURE 8: MEXICO CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY MORPHINE, IN 2023
FIGURE 9: MEXICO CANCER PAIN MANAGEMENT MARKET, BY FENTANYL, 2024-2032 (IN $ MILLION)
FIGURE 10: MEXICO CANCER PAIN MANAGEMENT MARKET, BY OTHER MORPHINES, 2024-2032 (IN $ MILLION)
FIGURE 11: MEXICO CANCER PAIN MANAGEMENT MARKET, BY NON-OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 12: MEXICO CANCER PAIN MANAGEMENT MARKET, BY ACETAMINOPHEN, 2024-2032 (IN $ MILLION)
FIGURE 13: MEXICO CANCER PAIN MANAGEMENT MARKET, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2024-2032 (IN $ MILLION)
FIGURE 14: MEXICO CANCER PAIN MANAGEMENT MARKET, BY NERVE BLOCKERS, 2024-2032 (IN $ MILLION)
FIGURE 15: MEXICO CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DISEASE INDICATION, IN 2023
FIGURE 16: MEXICO CANCER PAIN MANAGEMENT MARKET, BY LUNG CANCER, 2024-2032 (IN $ MILLION)
FIGURE 17: MEXICO CANCER PAIN MANAGEMENT MARKET, BY COLORECTAL CANCER, 2024-2032 (IN $ MILLION)
FIGURE 18: MEXICO CANCER PAIN MANAGEMENT MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)
FIGURE 19: MEXICO CANCER PAIN MANAGEMENT MARKET, BY PROSTATE CANCER, 2024-2032 (IN $ MILLION)
FIGURE 20: MEXICO CANCER PAIN MANAGEMENT MARKET, BY BLOOD CANCER, 2024-2032 (IN $ MILLION)
FIGURE 21: MEXICO CANCER PAIN MANAGEMENT MARKET, BY OTHER DISEASE INDICATIONS, 2024-2032 (IN $ MILLION)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧